C - The Ames test detects point mutations (TA100/TA1535) and frame-shift mutations (TA98/TA1537/TA1538) in Salmonella.
C - Microsomes (S9 mix) provide liver enzymes to metabolically activate procarcinogens into their mutagenic form.
C - HGPRT (hypoxanthine-guanine phosphoribosyl transferase) is used to detect mutations in the CHO cell test.
C - MutaMouse assay uses β-galactosidase reporter to detect mutations in every cell of the mouse.
C - Pig-a assay detects mutations in the gene required for GPI-anchor protein expression on red blood cells.
C - The micronucleus test detects chromosomal fragments or whole chromosomes not incorporated into daughter nuclei.
C - The comet assay visualizes and quantifies DNA strand breaks in individual cells using electrophoresis.
D - Chronic bioassays run for 2 years and are considered the gold standard for carcinogenicity testing.
C - MTD is the maximum dose that does not cause overt toxicity in a 90-day study, used for setting top dose levels.
C - TPA is a tumor promoter used in skin cancer models for evaluating initiation and promotion stages.
B - GSH-P (glutathione transferase pi) is a biomarker for early liver lesions in promotion studies.
B - Transgenic mice such as TgAC, rasH2, and P53 knockout are used in rapid carcinogenicity screening.
C - IARC is responsible for evaluating carcinogenic risks and classifying agents into Group 1–4 categories.
C - Group 1 IARC agents have sufficient evidence to be considered carcinogenic to humans.